• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$50.49 -$0.13 (-0.26%)

REAL-TIME: Last trade at

Gilead Sciences

NASDAQ:GILD

Jump to this page for:

Related Resources

7 Biotech Stocks to Add to Your Portfolio

5/26/2012 by InvestorPlace

Gilead Files European Marketing Application for Boosting Agent Cobicistat

5/24/2012 by PharmiWeb.com - UK

Gilead files European Marketing Application for boosting agent cobicistat

5/23/2012 by Theflyonthewall.com

Gilead Files European Marketing Application for Boosting Agent Cobicistat

5/23/2012 by Business Wire

Gilead Sciences Inc.: Strong Growth At A Low Price

5/21/2012 by Seeking Alpha

Gilead Sciences’ HIV Drugs Clear a Hurdle

5/17/2012 by InvestorPlace

Gilead likey to remain dominant in HIV treatment for some time, says Wells Fargo

5/17/2012 by Theflyonthewall.com

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb

5/15/2012 by PR Newswire

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation, Blue Nile and Bristol-Myers Squibb - Press Releases

5/15/2012 by Zacks Investment Research

Two Positive Advisory Committee Votes, Quad on Track for August Approval as Expected

5/14/2012 by Morningstar

Gilead Sciences, Inc.' HIV Quad Pill Wins Backing From FDA Advisers

5/14/2012 by BioSpace

A Health Care Fortnight for the Record Books

5/14/2012 by TheStreet.com

Research Reports for Chesapeake Energy, Bank of America, Ford, Ciena, Nuance Communications, and Gilead Sciences

5/14/2012 by PR Newswire

Gilead Quad approval will be important, says RW Baird

5/14/2012 by Theflyonthewall.com

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV

5/12/2012 by PharmiWeb.com - UK

Gilead Sciences HIV Drug Quad Gets FDA Panel Backing

5/11/2012 by RTTNews

Gilead Sciences (GILD) Gets FDA Advisory Committee Support of Quad HIV-1 Treatment

5/11/2012 by StreetInsider.com

FDA Advisory Committee Supports Approval of Gilead’s Once-Daily Quad Single Tablet Regimen for HIV

5/11/2012 by Business Wire

Gilead Sciences (GILD) Gets FDA Committee Support for Truvada

5/11/2012 by StreetInsider.com

FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV

5/10/2012 by Business Wire

FDA Anti-Viral Drugs Advisory Committee to hold a meeting

5/10/2012 by Theflyonthewall.com

AIDS Healthcare Foundation to host a teleconference

5/9/2012 by Theflyonthewall.com

Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16

5/9/2012 by PharmiWeb.com - UK

Gilead Sciences to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on Wednesday, May 16

5/8/2012 by Business Wire

Vertex Is the Next Gilead Sciences or Alexion

5/7/2012 by TheStreet.com

The FDA Pediatric Advisory Committee to hold a meeting

5/7/2012 by Theflyonthewall.com

Goldman Sachs Positive On Gilead Sciences (GILD) Ahead of Quad AdCom

5/7/2012 by StreetInsider.com

Lack of data on Bristol-Myers' hep C treatment raises red flag, The Street says

5/7/2012 by Theflyonthewall.com

Deutsche Bank's biotech analyst to hold a conference call

5/4/2012 by Theflyonthewall.com

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May [UPDATE]

5/2/2012 by Minyanville

Pharmacyclics shares should be bought on any weakness, says RBC Capital

5/2/2012 by Theflyonthewall.com

Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8

5/2/2012 by PharmiWeb.com - UK

Gilead starts Phase 3 trial evaluating GS-1101 for Leukemia treatment

5/1/2012 by Theflyonthewall.com

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment of Chronic Lymphocytic Leukemia

5/1/2012 by Business Wire

Gilead Sciences to Present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8

5/1/2012 by Business Wire

AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences

5/1/2012 by PR Newswire

Gilead Sciences Looks For Hepatitis C Cure

4/30/2012 by Seeking Alpha

Pfizer, Gilead Sciences, Arena Pharmaceuticals Face Big Dates in May

4/30/2012 by Minyanville

Merck Pins Hopes On Product Pipeline

4/27/2012 by Investor's Business Daily

Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Raising Numbers on Recent Progress in HCV

4/27/2012 by StreetInsider.com
See More Articles...